Ignite Creation Date:
2025-12-24 @ 10:58 PM
Ignite Modification Date:
2026-01-03 @ 6:11 AM
Study NCT ID:
NCT03774069
Status:
TERMINATED
Last Update Posted:
2025-11-19
First Post:
2018-12-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Advisor Pro Direct Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 100}}, 'statusModule': {'whyStopped': "It was finally decided not to perform the interventional part of the study. Only the questionnaire's part was performed", 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2020-12-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2023-12-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-11-16', 'studyFirstSubmitDate': '2018-12-11', 'studyFirstSubmitQcDate': '2018-12-11', 'lastUpdatePostDateStruct': {'date': '2025-11-19', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2018-12-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-12-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of glucose readings within range of 70-180 mg/dl (3.9 to 10mmol/L)', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'Percentage of readings below 54 mg/dl (3.3 mmol/l)', 'timeFrame': 'Final visit (week 12)'}], 'secondaryOutcomes': [{'measure': 'HbA1c', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'Diabetes treatment satisfaction questionnaire', 'timeFrame': 'Final visit (week 12)', 'description': 'The questionnaire contains 12-14 items (12 for the teens version and 14 for the parents version) the subscale for each items is from 0 to 6, and for most items the the higher the score, the greater the satisfaction with the treatment.Subscales are summed. More specific instruction for analysis are detailed in Diabetologia 52:(suppl 1) S397, Abstruct 1013 and in a document named "Summary of recommended scoring" by Prof. Bradley, University of London'}, {'measure': 'Percentage of glucose readings below 70 mg/dl (3.9 mmol/L)', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'Percentage of readings below 60 mg/dl (3.35mmol/L)', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'Percentage of readings above 180 mg/dl (10.0mmol/L)', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'percentage of readings above 250 mg/dl (13.9 mmol/L)', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'Area above the curve of glucose level of 180 mg/dl', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'Area above the curve of glucose level above180 mg/dl', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'Area under the curve of glucose level of 70 mg/dl', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'Area under the curve of glucose level below 70 mg/dl', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'Mean sensor blood glucose', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'Glucose variability measured by standard deviation', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'Number of recommendations sent to patient in the last 6 months prior to baseline and during intervention period', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'Number of recommendations for changes in settings per patient', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'Number of recommendations for changes in settings per iteration', 'timeFrame': 'Final visit (week 12)'}, {'measure': 'Number of physician override Advisor recommendation', 'timeFrame': 'Final visit (week 12)'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Insulin pump treatment', 'Type 1 diabetes', 'Pump setting advisor'], 'conditions': ['Type 1 Diabetes Mellitus']}, 'descriptionModule': {'briefSummary': "The DreaMed Advisor Pro is a software which automatically analyses treatment information, learns patient's needs and accordingly suggests adjustments in insulin dosing. DreaMed Advisor Pro is a decision- support software intended for assisting healthcare professionals in the management of type 1 diabetes patients who use insulin pumps as their insulin delivery therapy and monitor their blood glucose levels using CGM (Continuous Glucose Monitoring) or CGM and self-management blood glucose meter.\n\nThe main objective of the proposed study is to test the safety, reliability, and efficacy of the DreaMed Advisor Pro algorithm when the recommendation is sent directly to the patient without a physician review.\n\nParticipants will be randomized in a 1:1 ratio to either the intervention group (DreaMed Advisor Pro) or control group (standard of care). Participants will download the CGM and pump data at no less frequent than every 4 weeks for both groups during the 3 months period of the study.\n\nEach time new data is received, the following actions will be performed:\n\nIn the intervention group, a new algorithm recommendation for pump settings will be issued. The recommendation will be approved by a technical, non-physician to assure that glucose data are not fall within predefined safety criteria which require a physician approval before the recommendation will be sent to the patient, otherwise, recommendation will be sent directly to the patient.\n\nIn the control group, if no safety criteria is met, it is the responsibility of the patient to contact his/her physician to advise on change of treatment. In case a safety issue has occurred, the physician will contact the patient and change the pump settings.\n\nPrior to initiating the interventional phase of the study, we will evaluate the experience of patients in self adjustments of insulin dosing in regular care management and to evaluate their acceptance for using an automated dosing recommendations software. The evaluation will be done by asking patients/caregivers to fill 15 questions survey. 100 patients are anticipated to participate in this phase of the study."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Subject with type 1 diabetes (\\>1 yr diagnosis)\n2. Age- 6-30 years old\n3. HbA1c equals or above 7% and equals or below 10%\n4. Insulin infusion pump CSII (Continuous Subcutaneous Inulin Infusion) therapy for at least 4 months and current treatment with one of the following pumps: Omnipod Insulet (Bedford, MA), Medtronic Minimed Veo insulinPump (MMT-754, MMT-554), Medtronic 640G or Animas.\n5. BMI below 30 kg/m\\^2\n6. Patients willing to follow study instructions (willing to measure capillary blood glucose as required by their glucose sensor for calibration and use the bolus- calculator feature of the pump)\n7. Patients are required to have minimum computer skills and understanding of navigating the internet.\n8. Patients are required to know basic English.\n9. Patients willing to use glucose sensor for study duration.\n10. Patients will have to have a smartphone (Apple or Android) or PC with email account.\n\nExclusion Criteria:\n\n1. An episode of diabetic ketoacidosis within the month prior to study entry\n2. Any significant diseases/ conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise patient's safety.\n3. Current participation in any other interventional study.\n4. Known or suspected allergy to trial products such as adhesives, tapes, needles.\n5. Female subject who is pregnant or lactating or planning to become pregnant within the planned study duration\n6. Severe hypoglycemia within six months prior to enrollment as defined by the ADA and Endocrine society as follows: Severe hypoglycaemia is an event requiring assistance of another person (due to change in mental status) to actively administer carbohydrates, glucagon, or take othe corrective actions.\n7. Current use of the following medications: medications that are use to lower blood glucose such as Pramlintide, Metformin and GLP-1 analogs. Beta blockers, glucocorticoids and other medications, which in the judgment of the investigator would be a contraindication to participation in the study.\n8. Hypoglycemia unawareness\n9. Relevant severe organ disorders (diabetic nephropathy, diabetic retinopathy, diabetic foot syndrome) or any secondary disease or complication of diabetes mellitus.\n\n * Subject has unstable or rapidly progressive renal disease or is receiving dialysis.\n * Subject has active proliferative retinopathy.\n * Active gastroparesis\n10. Patient suffers from eating disorder. -"}, 'identificationModule': {'nctId': 'NCT03774069', 'briefTitle': 'The Advisor Pro Direct Study', 'organization': {'class': 'OTHER', 'fullName': 'Rabin Medical Center'}, 'officialTitle': 'Evaluation of Remote Consultation to Patients With Type 1 Diabetes Under Continuous Glucose Sensors and Insulin Pump Therapy Using the DreaMed Advisor Pro. An Open Label, Randomized Non-inferiority Study of Insulin Pump Therapy Adjustments Between DreaMed Advisor Pro and Standard of Care-The Advisor Pro Direct Study', 'orgStudyIdInfo': {'id': 'RMC040818ctil'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'DreaMed Advisor Pro', 'description': 'Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor pro.', 'interventionNames': ['Device: DreaMed Advisor Pro']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Control group- medical guided recommendation', 'description': 'Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted by the medical team', 'interventionNames': ['Other: Medical guided recommendation']}], 'interventions': [{'name': 'DreaMed Advisor Pro', 'type': 'DEVICE', 'description': 'Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro and sent directly to the patient', 'armGroupLabels': ['DreaMed Advisor Pro']}, {'name': 'Medical guided recommendation', 'type': 'OTHER', 'description': 'Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team according to standard of care', 'armGroupLabels': ['Control group- medical guided recommendation']}]}, 'contactsLocationsModule': {'locations': [{'zip': '49202', 'city': 'Petah Tikva', 'country': 'Israel', 'facility': "Schnider Children's medical center", 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Rabin Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'DreaMed', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}